Breast Cancer Liquid Biopsy Market Report Analysis, Research Studies | Thermo Fisher Scientific Inc, Abbott & Medtronic.

The Global Breast Cancer Liquid Biopsy Market was valued at USD 1.6 billion in 2023 and is projected to reach USD 7.98 billion by 2031, expanding at a CAGR of 23.2% during the forecast period 2024-2031.

A liquid biopsy is a non-invasive test performed on a sample of blood, urine, or other body fluids to detect cancer cells, fragments of DNA, RNA, or other molecules released by tumor cells. This technique allows for multiple samples over time, aiding in monitoring genetic or molecular changes in tumors. Liquid biopsies are valuable for early cancer detection, treatment planning, assessing treatment effectiveness, and detecting cancer recurrence.

Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/breast-cancer-liquid-biopsy-market

Market Dynamics:

Increasing prevalence of breast cancer

• Rising Prevalence of Breast Cancer: Breast cancer is the most commonly diagnosed cancer among women worldwide, accounting for 1 in 4 cancer cases. In 2022, there were approximately 2.3 million new cases and 669,418 deaths globally, with many deaths occurring in low-resource settings.

• Increasing Awareness and Technological Advancements: Growing awareness of breast cancer and advancements in liquid biopsy technology are driving demand. About 66% of breast cancer cases are detected at a localized stage, which is more treatable.

• High Incidence Rates: Over 4 million women in the US have a history of breast cancer. Breast cancer remains the leading cause of cancer death among women in 95% of countries, highlighting the need for effective diagnostic and monitoring tools.

• Global Disparities in Survival Rates: Nearly 80% of breast cancer deaths occur in low- and middle-income countries, emphasizing the need for accessible and equitable diagnostic solutions.

Market Segmentation:

By Product Type: Reagents & Kits, Instruments.

By Circulating Biomarkers: Circulating Tumor Cells (CTCs), Circulating Cell-free DNA (cfDNA), Extracellular Vesicles, Others.

By Application: Early Screening, Treatment Selection.

By End-users: Hospitals, Diagnostic Centers, Research and Educational Institutions, Others.

Get Customization in the report as per your requierments: https://datamintelligence.com/customize/breast-cancer-liquid-biopsy-market

Major Key Players:

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott
• Agilent Technologies Inc.
• Merck KGaA
• Cell Signaling Technology Inc.
• Medtronic
• Bio-Rad Laboratories Inc.
• ExoDx
• Biocept Inc.

Regional Analysis:

The global Breast Cancer Liquid Biopsy Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Breast Cancer Liquid Biopsy Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.

Related Reports:

Wearable Medical Devices Market: https://datamintelligence.com/research-report/wearable-medical-devices-market

Medical Supplies And Equipments Market: https://datamintelligence.com/research-report/medical-supplies-and-equipments-market

Affiliate Marketing Request here: https://www.datamintelligence.com/affiliate-marketing

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.